Anticancer Drugs Oncology Pharmacology Physiotherapy Ramucirumab

Ramucirumab (23)

In this article, we will discuss Ramucirumab (23). So, let’s get started.

Clinical Trials Experience (3)

Across clinical trials of Ramucirumab administered as a single agent, clinically relevant adverse reactions (including
Grade ≥3) reported in Ramucirumab-treated patients included proteinuria, gastrointestinal perforation, and infusion-related reactions. In Study 1, according to laboratory assessment, 8% of Ramucirumab-treated patients developed proteinuria versus
3% of placebo-treated patients. Two patients discontinued Ramucirumab due to proteinuria. The rate of gastrointestinal
perforation in Study 1 was 0.8% and the rate of infusion-related reactions was 0.4%.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.